Damora Therapeutics (DMRA) Other Operating Expenses (2019 - 2025)

Damora Therapeutics (DMRA) has 4 years of Other Operating Expenses data on file, last reported at $174.3 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses rose 3866.1% year-over-year to $174.3 million; the trailing twelve-month figure through Mar 2026 stood at $174.3 million (up 3150.23% YoY), and the FY2025 full-year result was $174.3 million, up 3150.23% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $174.3 million, up from $4.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $174.3 million in Q4 2025 and bottomed at $720000.0 in Q4 2023.
• The 3-year median for Other Operating Expenses is $2.7 million (2023), against an average of $36.6 million.
• The widest annual swing landed in 2024, when Other Operating Expenses jumped 510.42%; it then surged 3866.1% in 2025.
• A 3-year view of Other Operating Expenses shows it stood at $720000.0 in 2023, then surged by 510.42% to $4.4 million in 2024, then soared by 3866.1% to $174.3 million in 2025.
• The last three Other Operating Expenses figures came in at $174.3 million (Q4 2025), $4.4 million (Q4 2024), and $968000.0 (Q2 2024), per Business Quant data.

Peer Comparison